Cencora Inc.
02/10/2026 | Press release | Distributed by Public on 02/10/2026 07:47
EXPLANATORY NOTE (Form 8-K)
EXPLANATORY NOTE
Cencora, Inc. (the "Company" or "Cencora") is filing this exhibit to its Current Report on Form 8-K (the "Form 8-K") to reflect a revision to the presentation of its financial information as set forth in its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (the "2025 Form 10-K"), as filed with the Securities and Exchange Commission ("SEC") on November 25, 2025, to give effect to a change in its segment reporting.
As previously disclosed, the Company undertook a strategic review of its business to ensure alignment with its growth priorities and strategic drivers. As a result of this review, beginning in the first quarter of fiscal 2026, the Company reorganized certain business components within its reporting structure. The Company's revised reporting structure is comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment consists of U.S. Human Health (excluding legacy U.S. Consulting Services). The International Healthcare Solutions reportable segment consists of Alliance Healthcare, Innomar, World Courier, and strategic components of Pharmalex. Other, which is not considered a reportable segment, consists of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services, and the other components of Pharmalex. The Company began to report under this revised reporting structure effective with the Quarterly Report on Form 10-Q for its fiscal year 2026 first quarter ended December 31, 2025 (the "2026 Q1 Form 10-Q"), which was filed with the SEC on February 4, 2026.
This exhibit revises the previously reported segment results in the following Items of the 2025 Form 10-K to conform to the Company's re-aligned reporting structure described above: Part I, Item 1. Business; Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations; and Part II, Item 8. Financial Statements and Supplementary Data.
The information included in this exhibit is presented for informational purposes only in connection with the revised reporting structure described above and does not amend or restate the Company's audited consolidated financial statements, which were included in the 2025 Form 10-K. This exhibit does not reflect events occurring after the filing of the 2025 Form 10-K and does not modify or update the disclosures therein in any way, other than to illustrate the impact of the revised reporting structure as described above. For developments subsequent to the filing of the 2025 Form 10-K, refer to the 2026 Q1 Form 10-Q.
Cencora Inc. published this content on February 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 10, 2026 at 13:47 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]